Patent intelligence · US
US 11459357
Polymyxin compounds
Polymyxin compounds
Patent details — US 11459357
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 4, 2022
- Expiration
- Sep 29, 2042
- Applicant
- SPERO THERAPEUTICS, INC.
- Claims
- 14
- CPC classes
- A61K, A61K38/00, A61K38/12
Quick answer
US 11459357 (Polymyxin compounds) is held by SPERO THERAPEUTICS, INC.. Status: granted. Granted Oct 4, 2022. Expires Sep 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SPERO THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K38/00, A61K38/12
More from SPERO THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428395
Heterocyclic compounds as kinase inhibitor and uses thereof
granted -
US 12291548
Compounds, compositions, and methods for the treatment of disease
granted -
US 12226403
Tebipenem pivoxil immediate and modified release oral dosage forms
granted -
US 12146004
Polymyxin compounds and uses thereof
granted -
US 12098155
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
granted -
US 12048691
High dosage tebipenem pivoxil tablet formulation
granted -
US 11718621
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
granted
Frequently asked questions
What is US patent 11459357?
US 11459357 (Polymyxin compounds) is held by SPERO THERAPEUTICS, INC.. Status: granted. Granted Oct 4, 2022. Expires Sep 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11459357?
SPERO THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.
When does US 11459357 expire?
Our index shows an expiration date of Sep 29, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.